EASL-ERN position paper on liver involvement in patients with Fontan-type circulation

Luis Téllez1, Audrey Payancé2, Eric Tjwa3

  • 1Gastroenterology and Hepatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas), University of Alcalá, Madrid, Spain.

Journal of Hepatology
|October 20, 2023
PubMed

Insights

Fontan-associated liver disease (FALD) affects nearly all patients with Fontan circulation. This paper defines FALD, aids staging, and offers management recommendations for improved Fontan patient outcomes.

Area of Science:

  • Cardiology
  • Hepatology
  • Pediatric Surgery

Background:

  • Fontan-type surgery is a critical palliative treatment for univentricular heart defects.
  • Long-term hemodynamic changes post-Fontan surgery invariably lead to liver damage, termed Fontan-associated liver disease (FALD).
  • The precise impact of FALD on Fontan patient prognosis is unclear due to undefined criteria and competing risks.

Framework:

  • This position paper establishes a clear definition and description of FALD.
  • It outlines clinical, analytical, radiological, hemodynamic, and histological features of FALD.
  • The paper provides guidance for staging liver disease in Fontan patients.

Implementation:

  • The paper offers evidence- and experience-based recommendations for managing FALD.
  • It addresses various clinical scenarios encountered in Fontan-associated liver disease.
  • The goal is to standardize FALD assessment and treatment.

Implications:

  • Standardizing FALD definition and staging will clarify its prognostic impact.
  • Evidence-based management recommendations aim to improve long-term outcomes for Fontan survivors.
  • This paper supports better clinical decision-making for patients with Fontan circulation and liver disease.